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Abstract An association among the occurrence of anti-
drug antibodies (ADAs), diminished trough serum drug
levels (TSDLs) and non-response or loss of response has
been described for several tumor necrosis factor alpha
(TNF) blocking agents in a variety of diseases, including
psoriasis. In a series of ten psoriasis patients with primary
or secondary failure, or adverse reactions during anti-TNF
therapy, we measured ADAs and TSDLs in patient serum
using radioimmunoassay and ELISA, respectively. By
proposing a treatment algorithm derived from research in
this field, we show that measuring ADAs and TSDLs in
psoriasis patients provides a more structured approach to
clinical decision making for psoriasis patients who fail
anti-TNF therapy.
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Introduction
Biologic agents such as the tumor necrosis factor alpha
(TNF) antagonists etanercept, adalimumab and infliximab,
as well as the interleukin (IL)-12/IL-23 antagonist us-
tekinumab, are available for the treatment of moderate to
severe plaque psoriasis [9]. Although these biologics have
proven to be highly efficacious, a significant number of
patients will discontinue their first biologic because of
primary failure (lack of initial efficacy), secondary failure
(loss of efficacy with time) or because of adverse reactions
[16]. For clinicians considering the treatment options for a
patient who has failed one TNF antagonist, it remains a
challenge to determine the optimal next therapeutic step. In
current clinical practice, drug switching is carried out
without the knowledge of factors that may explain the
failure.
An association between the occurrence of antidrug
antibodies (ADAs), diminished trough serum drug levels
(TSDLs) and non-response or loss of response has been
described for several biologics in a variety of diseases,
including psoriasis [3, 14, 25]. Nevertheless, studies
investigating immunogenicity in psoriasis are scarce, and
most of our current knowledge comes from studies in
patients with rheumatoid arthritis (RA) or Crohn’s disease
[14]. By presenting ten cases of psoriasis patients with
primary or secondary failure, or adverse reactions to a TNF
antagonist and reviewing relevant articles, we want to show
the clinical relevance of measuring TSDLs and/or ADAs in
psoriasis patients and how this can direct a clinician’s
decision making.
Materials and methods
Ten patients with primary or secondary failure, or adverse
reactions to a TNF antagonist (infliximab, etanercept, ada-
limumab) were seen at the Department of Dermatology at
the Ghent University Hospital. Treatment success was
defined as achieving PASI 75 and treatment failure when
PASI 50 was not achieved, according to the European con-
sensus guidelines [22]. Serum was collected at drug trough
level (just before next administration of the drug), and
the samples were analyzed at The Laboratory for Mono-
clonal Therapeutics, Sanquin Diagnostics, Amsterdam (the
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Netherlands). ADAs were detected by radioimmunoassay
(RIA) and TSDLs were measured by enzyme linked
immunosorbent assay (ELISA). The antibody test was
considered positive when antibody concentrations exceeded
12 AE/ml. Therapeutic TSDLs are: adalimumab C5 lg/ml,
infliximab C1 lg/ml and etanercept C2 lg/ml (values
provided by Sanquin Diagnostics, Amsterdam, the
Netherlands).
Results
Primary failure
Patient 1 did not respond to treatment with adalimumab
and had a pronounced psoriasis exacerbation after
20 weeks. Anti-adalimumab antibodies were negative, and
TSDLs were adequate (13 lg/ml). We continued treatment
and after 24 weeks PASI 50 was achieved, and PASI 100
after 35 weeks.
Patient 2 had not achieved PASI 75 after 16 weeks of
treatment with adalimumab. Testing showed no ADAs and
adequate TSDLs (7 lg/ml). Finally, after 21 weeks of
treatment, PASI 75 was achieved. Unfortunately, 8 weeks
later, psoriasis relapsed. With addition of methotrexate
(MTX) 7.5 mg/week, PASI 75 was achieved after
2 months. The patient is currently still in remission (1 year
and 9 months later).
Secondary failure
Patient 3 received adalimumab treatment for 1 year,
stopped treatment for 6 weeks, and was subsequently non-
responsive to treatment for the following 7 months. Anti-
adalimumab antibodies (800 AE/ml) were present in the
patient’s serum at this point in time, yet TSDLs were
undetectable as treatment had already been interrupted.
Therapy was subsequently switched to ustekinumab, and
PASI 100 was achieved after 12 weeks.
Patient 4 rapidly responded to adalimumab, but became
non-responsive after 9 months. Temporary addition of
MTX 5 mg/week (3 months) had no effect. Anti-ada-
limumab antibodies were detected (18 AE/ml), but TSDLs
were within therapeutic range (14 lg/ml). Therapy was
switched to infliximab, but treatment was prematurely
discontinued (see adverse reactions). Good clinical
response was achieved by switching to ustekinumab.
Patient 5 achieved a PASI 75 during treatment with
infliximab and MTX (5 mg/week), but became non-
responsive after 7 months. TSDLs were subtherapeutic, but
no ADAs were detected. A good clinical response was
achieved using ustekinumab. After 2 years treatment with
infliximab, Patient 6 also became non-responsive but no
ADAs were detected and TSDLs were therapeutic (17 lg/
ml). Addition of MTX (5 mg/week) was sufficient to
achieve disease control.
Patient 7 was successfully treated with etancercept for
2 years, after which psoriasis relapsed. Switching to ada-
limumab restored clinical response, but after 4 months
psoriasis exacerbated again. Anti-adalimumab antibodies
were positive (24 AE/ml). Readministration of etanercept
for 18 months was unsuccessful. No anti-etanercept anti-
bodies were detected, but TSDLs were subtherapeutic
(0.3 lg/ml). Dose escalation (2 9 50 mg/w) did not
improve efficacy. By switching to ustekinumab, PASI 75
was finally achieved.
Patient 8 became non-response to infliximab therapy
after 1 year. Anti-infliximab antibodies were positive
(2,900 AE/ml). Psoriasis improved by switching to eta-
nercept, but the patient became non-responsive after
1.5 years of treatment. No anti-etanercept antibodies were
detected. Subsequent treatment with ustekinumab was
successful.
Adverse reactions
Patient 4 developed nausea, flushing, itching during inf-
liximab infusion and treatment was subsequently termi-
nated. No anti-infliximab antibodies were detected (1 year
later).
Patient 9 developed a skin rash after 4 weeks etanercept
treatment. This skin rash was pathologically scored as a
vacuolopathic parakeratotic interphase dermatitis, indicat-
ing a toxic reaction to medication. No anti-etanercept
antibodies were detected. Good clinical response was
achieved with ustekinumab.
Patient 10 developed erythroderma during etanercept
treatment. No anti-etanercept antibodies were detected.
Therapy was switched to infliximab, but after two suc-
cessful treatment years, psoriasis relapsed with the devel-
opment of anti-infliximab antibodies (230 AE/ml).
Switching to ustekinumab gave good disease control.
Discussion
In the 2 patients we describe with primary failure (patient 1
and 2), testing showed adequate TSDLs and no ADAs.
Findings in RA patients suggest that the absence of ADAs
in non-responders might reflect a lack of responsiveness to
the mechanism of action shared by all anti-TNF agents and
indicates the need to switch to a drug with a different
mechanism of action [3, 11]. Accordingly, in patient 1 and
2, a switch to ustekinumab would be recommended (see
Fig. 1a). Although some authors have showed the effec-
tiveness and tolerability of switching between biologics in
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Fig. 1 Proposed treatment algorithm for psoriasis patients with
primary or secondary failure, or adverse reactions to TNF antagonists
a Primary or secondary failure to adalimumab or infliximab.
Combining the results of trough serum drug levels (TSDLs) and
anti-drug antibodies (ADAs) results in the following options: if the
TSDLs are low, and no ADAs are detected, it is firstly important to
ensure a good adherence. Concomitant treatment or intensification of
treatment (increasing dosage or decreasing treatment interval) can be
considered. In the case of therapeutic TSDLs without ADA formation,
we recommend to wait until 24 weeks of treatment has passed before
switching to a biologic with another mechanism of action. Concom-
itant therapy may be considered. When ADAs are present, both
switching to an alternative TNF antagonist or a biologic with another
mechanism of action are good options. b Primary or secondary failure
to etanercept. In patients treated with etanercept, ADAs are reported
to be non-neutralizing, and therefore only TSDLs are considered. If
TSDLs are within the therapeutic range, we recommend switching to
a biologic with another mechanism of action after a treatment period
of 24 weeks. Concomitant therapy may be considered. In the case of
low or subtherapeutic TSDLs, intensification of treatment, ensuring a
good adherence, and/or concomitant therapy may enhance efficacy.
c Adverse reaction to adalimumab, infliximab or etanercept. In the
case of adverse reactions, the value of ADA or TSDL testing is
questionable. Both a switch to an alternative TNF antagonist and a
biologic with another mechanism of action are good options
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psoriasis patients [13], it is not recommended to switch too
often as intermittent treatment or re-exposure after a
treatment free interval may be associated with an increase
in immunogenicity [1, 15]. The National Institute for
Health and Clinical Excellence (NICE) recommends
evaluating the treatment success of biologics at 10 weeks
for infliximab, 12 weeks for etanercept and 16 weeks for
both adalimumab and ustekinumab [24]. However, in
several studies, even more patients achieved PASI 75 after
24 weeks [17, 18, 21, 23]. Therefore, we recommend
waiting at least 24 weeks before concluding the treatment
is not working, particularly when ADAs are not detected,
to avoid potentially unnecessary switching. Concomitant
treatment may be considered as this may enhance efficacy
[24] (Fig. 1a, b). Accordingly, as in patient 1 and 2 no
ADAs were detected and TSDLs were adequate, we
extended treatment and no switch was required as both
patients achieved PASI 75 at 24 weeks.
In patients 3 and 4, secondary failure was associated
with anti-adalimumab antibodies. Based on the literature, a
switch to another TNF antagonist can be efficacious in such
cases, as ADAs do not crossreact [3, 11, 16] (Fig. 1a).
Unfortunately, patient 4 developed an infusion reaction
during the first administration of infliximab, and therapy
was switched to ustekinumab with good response.
Patient 5 became unresponsive to infliximab treatment.
No ADAs were detected, but infliximab serum levels were
subtherapeutic. In patients with subtherapeutic concentra-
tions, infliximab dose escalation (i.e. increasing the dose or
shortening of the administration interval between infu-
sions) has been associated with a significantly increased
clinical response compared to changing to another anti-
TNF [2]. Another study also reported dose escalation to be
a good choice in patients negative for ADAs with low
serum infliximab levels [26]. Unfortunately, due to gov-
ernmental reimbursement restrictions, dose escalation
could not be performed in our patient. Patient 6 also
became unresponsive to infliximab. No ADAs were
detected, and TSDLs were therapeutic. Detectable inflix-
imab trough concentrations have been associated with
better clinical remission rates [19], but as discussed earlier;
addition of concomitant treatments may enhance efficacy
[8, 24]. Therefore, we decided to maintain the treatment
dosing schedule in our patient, but additionally prescribed
MTX (Fig. 1a) which resulted in an improved treatment
efficacy.
In patient 7, readministration of etanercept therapy after
adalimumab failure was not successful. No ADAs were
detected, but TSDLs were subtherapeutic. Potential
explanations for low TSDLs without ADA formation
include patient non-compliance, or an inadequate drug
dosage for the degree of inflammation as has been descri-
bed for infliximab [7, 26]. Thus, patient 7 was treated with
an increased dose of etanercept. Unfortunately, the patient
remained non-responsive. Similarly, in patient 8, switching
to etanercept after previous TNF-antagonist failure was not
successful. Although etanercept may represent an effective
and well-tolerated alternative treatment for psoriasis
patients who have failed to respond to other therapies
(traditional or biologic), it has been reported that etanercept
was more effective in biologic naive patients [20]. How-
ever, the rate of response to a second TNF antagonist is
usually inferior to that of the first [16]. On the other hand,
patients who discontinued their first anti-TNF agent due to
adverse effects are more likely to respond to another TNF
antagonist than those who experienced inefficacy [10].
Adverse reactions were observed in patients 9 and 10
during treatment with etanercept. Patient 10 indeed
responded well to a switch to infliximab. However, after
2 years, ADAs against infliximab developed and therapy
was switched to ustekinumab. In patient 9, therapy was
immediately switched to ustekinumab. Patient 4 developed
an acute infusion reaction to infliximab. No anti-infliximab
antibodies were detected (1 year later). Although anti-inf-
liximab antibodies may favor the occurrence of infusion
reactions, their presence is not specific [4].
From a clinical and economic perspective, testing of
ADAs and TSDLs may not be worthwhile in the case of
Table 1 Trough serum drug levels and anti-drug antibody levels of
10 psoriasis patients
Patient Biologic
agent
TSDLsa
(lg/ml)
ADAsb IgG
totaal (AE/ml)
Primary
(P) or
secondary
(S) failure,
or adverse
(A) reaction
1 Adalimumab 13 \12 P
2 Adalimumab 7 \12 P
3 Adalimumab \0.002 800 S
4 Adalimumab 14 18 S
Infliximab N/A \12 (after 1 year) A
5 Infliximab 0.7 \12 S
6 Infliximab 17 \12 S
7 Adalimumab \0.002 24 S
Etanercept 0.3 \12 S
8 Infliximab \0.002 2900 S
Etanercept 3 \12 S
9 Etanercept \0.007 \12 A
10 Etanercept \0.002 \12 A
Infliximab \0.002 230 S
Italic blood drawn after discontinuation of treatment
a Therapeutic TSDLs adalimumab C5 lg/ml, infliximab C1 lg/ml,
etanercept C2 lg/ml (values provided by Sanquin Diagnostics,
Amsterdam, the Netherlands)
b ADAs positive [12 AE/ml
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adverse reactions as switching is the only option in the case
of severe adverse reactions [15]. In such a setting, different
TNF-antagonists or biologics with different mechanisms of
action are viable treatment alternatives (Fig. 1c).
In none of the patients treated with etanercept (patients
7, 8, 9 and 10), ADAs against the drug were detected. In
general, anti-etanercept antibodies have only been reported
scarcely [6]. However, two studies in RA patients showed
that non-responders to etanercept obtain lower serum drug
levels compared to responding patients [5, 12]. Therefore,
in etancercept-treated patients, we suggest to only consider
testing of TSDLs. In the case of subtherapeutic etanercept
trough levels, we propose the etanercept dosage to be
increased. In the case of therapeutic trough levels, a switch
to another class is recommended (Fig. 1b).
Despite some methodological shortcomings with respect
to blood samples drawn from patients post-treatment (see
Table 1), we show that measuring ADAs and/or TSDLs
can guide a dermatologist’s decision-making process in a
more pragmatic way. Looking at TNF antagonists from a
pharmacological point of view (measuring therapeutic
trough levels and titrate dose accordingly) is rather new,
and could in the future help us to dose these drugs in a
more cost effective manner (e.g., in case of good response
and high trough levels one could lower the dose of drug).
In conclusion, we show on a case-by-case basis that
measuring ADAs and TSDLs can optimise biologic treat-
ment in psoriasis patients. Our report provides a first step
towards a more structured approach when dealing with
non-response or loss of response to biologics. Our pre-
liminary treatment algorithm provides a new viewpoint,
which encompasses the currently available literature. Fur-
ther research is needed to clarify its applicability to
improve the outcomes of patients treated with TNF
antagonists.
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